Seminars in Oncology Nursing
Volume 23 , Pages S3-S9 , November 2007

Choosing the Appropriate Breast Cancer Therapy for Today's Breast Cancer Patient

  • Cynthia Frankel

      Affiliations

    • Corresponding Author InformationAddress correspondence to Cynthia Frankel, RN, OCN®, Memorial Regional Hospital/Cancer Center, 1150 N 35th Ave, Suite 170, Hollywood, FL 33021

References 

  1. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: principles & practice of oncology. Philadelphia, PA: Lippincott Williams & Williams; 2007;
  2. American Cancer Society . Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007;
  3. Clark M, Collins R, Darby S. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  4. Lerner BH. The breast cancer wars. New York, NY: Oxford University Press; 2001;
  5. National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology: breast cancer. Jenkintown, PA: National Comprehensive Cancer Network; 2007;
  6. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441–452
  7. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–1241
  8. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–1232
  9. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med. 1995;333:1444–1455
  10. Arriagada R, Le MG, Rochard F, et al. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol. 1996;14:1558–1569
  11. Arthur DW, Morris MM, Vicini FA. Breast cancer: new radiation treatment options. Oncology (Williston Park). 2004;18:1621–1629
  12. Sanghani M, Mignano J. Intensity modulated radiation therapy: a review of current practice and future directions. Technol Cancer Res Treat. 2006;5:447–450
  13. Stanford Cancer Center. Radiation Therapy. Available at: http://cancer.stanfordhospital.com/forPatients/services/radiationTherapy/respiratoryGating/default (accessed August 2, 2007).
  14. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D^ metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2006;101:113–121
  15. NSABP study confirms Oncotype DX predicts chemotherapy benefit in breast cancer patients. Oncology (Williston Park). 2006;20:789–790
  16. Kaklamani VG, Gradishar WJ. Gene expression in breast cancer. Curr Treat Options Oncol. 2006;7:123–128
  17. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–3734
  18. Pollack A. Test to predict breast cancer relapse is approved. New York Times. February 7, 2007.
  19. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353:1652–1654
  20. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  21. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(suppl 2):21–26
  22. Baselga J, Perez EA, Pienkowshi T, et al. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist. 2006;11:4–12
  23. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  24. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  25. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  26. Tan-Chiu E, Piccart M. Moving forward: Herceptin in the adjuvant setting. Oncology. 2002;63(suppl 1):57–63
  27. Beslija S, Bonneterre J, Burstein H, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2006;18:215–225
  28. Xeloda package insert. Nutley, NJ: Roche Pharmaceuticals; 2006;
  29. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743
  30. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21:2101–2109
  31. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 2000;18:1399–1411
  32. Jones S, Vogel C, Arkhipov A, et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol. 1999;17:3418–3425
  33. Herceptin package insert. South San Francisco, CA: Genentech, Inc.; 2006;
  34. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001;1:85–94
  35. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist. 2006;11:1047–1057
  36. Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A. 2006;103:7795–7800
  37. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6:714–727
  38. Nahta R, Yu D, Hung MC, et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3:269–280
  39. Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun. 2004;319:1–11
  40. Chu I, Blackwell K, Chen S, et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005;65:18–25
  41. Tykerb prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2007;
  42. US National Institutes of Health. Available at: http://www.clinicaltrials.gov/ct/action/ChangeQuery (accessed July 1, 2007).
  43. Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer. 2003;3:421–422
  44. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(suppl 3):20–29

 The development of this article was based on a presentation given by C. Frankel at the 2006 Oncology Nursing Society's 7th Annual Institutes of Learning; the author received an honorarium through an educational grant from GlaxoSmithKline.

PII: S0749-2081(07)00089-7

doi: 10.1016/j.soncn.2007.10.002

Seminars in Oncology Nursing
Volume 23 , Pages S3-S9 , November 2007

Article Tools

* Image Usage & Resolution